Merck, Inc.
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 180
- Registration Number
- NCT05468697
- Locations
- 🇺🇸
Georgetown University Medical Center ( Site 1002), Washington, District of Columbia, United States
🇺🇸University of Chicago Medical Center ( Site 1007), Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 1001), Boston, Massachusetts, United States
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
- Conditions
- Alzheimer Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT05466422
- Locations
- 🇺🇸
California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0007), Glendale, California, United States
🇺🇸Collaborative Neuroscience Research, LLC ( Site 0009), Los Alamitos, California, United States
🇺🇸NRC Research Institute ( Site 0015), Orange, California, United States
A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2162
- Registration Number
- NCT05464420
- Locations
- 🇺🇸
L&C Professional Medical Research Institute ( Site 0012), Miami, Florida, United States
🇺🇸Desert Clinical Research/ CCT Research ( Site 0019), Mesa, Arizona, United States
🇺🇸Valley Clinical Trials, Inc. ( Site 0023), Northridge, California, United States
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
- Conditions
- Mantle Cell LymphomaRichter Transformation LymphomaChronic Lymphocytic LeukemiaFollicular Lymphoma
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 223
- Registration Number
- NCT05458297
- Locations
- 🇺🇸
Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska, United States
🇺🇸Banner MD Anderson Cancer Center ( Site 0040), Gilbert, Arizona, United States
🇺🇸Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036), Phoenix, Arizona, United States
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)
- Conditions
- Papillomavirus Infections
- Interventions
- Biological: 9vHPV vaccine
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1500
- Registration Number
- NCT05450705
- Locations
- 🇨🇳
Jiangshan Center for Disease Control and Prevention ( Site 0001), Quzhou, Zhejiang, China
🇨🇳Yuhuan Center for Disease Control and Prevention ( Site 0002), Taizhou, Zhejiang, China
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05450198
- Locations
- 🇺🇸
AXIS Clinicals ( Site 0029), Dilworth, Minnesota, United States
🇨🇦Innovaderm Research Inc. ( Site 0019), Montréal, Quebec, Canada
🇺🇸Progressive Clinical Research ( Site 0022), San Antonio, Texas, United States
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
- Conditions
- High-grade Serous Ovarian CarcinomaOvarian Carcinoma
- Interventions
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT05446870
- Locations
- 🇨🇳
Changhua Christian Hospital-Obstetrics and Gynecology ( Site 1203), Changhua County, Changhua, Taiwan
🇪🇸Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101), Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1104), Madrid, Madrid, Comunidad De, Spain
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2663
- Registration Number
- NCT05425732
- Locations
- 🇺🇸
Baptist Health Center For Clinical Research ( Site 0019), Little Rock, Arkansas, United States
🇺🇸Millennium Clinical Trials ( Site 0013), Simi Valley, California, United States
🇺🇸Alliance for Multispecialty Research, LLC ( Site 0015), Coral Gables, Florida, United States
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)
- Conditions
- Pneumonia, Pneumococcal
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 717
- Registration Number
- NCT05420961
- Locations
- 🇮🇱
Maccabi Health Services - Holon ( Site 0305), Holon, Israel
🇮🇱Maccabi Healthcare Services ( Site 0306), Jerusalem, Israel
🇮🇱Meir Medical Center ( Site 0301), Kfar Saba, Israel
A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 53
- Registration Number
- NCT05406440
- Locations
- 🇺🇸
California Clinical Trials Medical Group managed by PAREXEL ( Site 0002), Glendale, California, United States
🇺🇸Hassman Research Institute Marlton Site ( Site 0003), Marlton, New Jersey, United States
🇺🇸Collaborative Neuroscience Research, LLC ( Site 0004), Garden Grove, California, United States